drugset / Trial / NCT00093912

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

NCT00093912

Phase 3 Completed 739 enrolled The Medicines Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to establish the safety of clevidipine in the treatment of perioperative hypertension. Approximately 250-500 patients with perioperative hypertension undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or sodium nitroprusside.

Timeline

Start
2004-06
Primary completion
2006-10
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevidipine Small molecule 3.2 ug/kg Intravenous
Comparator Sodium Nitroprusside Unknown Intravenous

Indications